Nohla signs WuXi AppTec to make cell therapies for bone marrow function

By Flora Southey contact

- Last updated on GMT

GettyImages/Duncan Smith
GettyImages/Duncan Smith
Nohla Therapeutics has selected WuXi AppTec Advanced Therapies to make its lead candidate, indicated to treat patients with hematologic malignances.

Under the commercial agreement, contract development and manufacturing organisation (CDMO) WuXi AppTec will use cell culture and expansion capabilities to make NLA101 at its 55,000 sq. ft. facility in Philadelphia Navy Yard, Pennsylvania.

The facility is dedicated to allogeneic and autologous cell-based therapeutics commercial manufacturing.

NLA101 as a universal donor, off-the-shelf, ex vivo ​expanded hematopoietic stem and progenitor cell product, designed to provide the support of bone marrow in patients with hematologic disorders and other critical diseases.

“The product consists of rapidly repopulating hematopoietic stem/progenitor cells (HSPCs) manufactured by culture of cord blood derived CD34+ cells on a proprietary platform with an engineered Notch ligand, Delta1,” ​Nohla spokesperson DeNike explained.

According to the firm, it provides rapid, transient haematopoiesis with long-term benefits.

“NLA101 was intentionally developed to be a short-term therapy that provides temporary bone marrow function that persists two to three weeks, until a patient’s immune system recovers while inducing long-term immunologic benefits with the potentially for improved survival.”

The cell therapy is manufactured ahead of time, and frozen – cryopreserved – for immediate use.

“NLA101 is differentiated from other autologous or patient-specific allogeneic cell therapies as it does not require tissue matching,” ​DeNike told us.

This is the first time Nohla has partnered with WuXi. 

“We are excited to partner with WuXi AppTec Advanced Therapies to gain their expertise and current good manufacturing practice (cGMP) manufacturing capabilities to support the ongoing development and anticipated global commercial demand for our lead cell therapy programme,” ​said DeNike.

Related news

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Related suppliers

Follow us


View more